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introduction
The stage of the disease of patients with non-small-cell
lung cancer (NSCLC) should be evaluated according to the
extent of the primary tumour (T-stage) as well as the spread to
regional or distant lymph nodes (N-stage) or organs (M-stage).
The TNM staging system is still the best predictor for
prognosis and has the most influence on the selection of
a tailored therapy. In general, surgery is the treatment of
choice for patients in whom the NSCLC is confined to the lung
and hilar lymph nodes.When lymph nodemetastases are present
in the ipsilateral mediastinum, a multimodality approach is
indicated, including chemo- or chemo/radiotherapy followed by
surgery for cases which would result in a complete resection.
When the contralateral lymph nodes in the mediastinum are
involved or distant metastases present, chemotherapy,
radiotherapy or both are the treatment of choice and surgery is
limited to few indications only.
non-invasive staging
Non-invasive staging is based primarily on chest computed
tomography (CT) and, if available, on positron emission
tomography (PET). The combination of both is best applied with
an integrated PET–CT approach. Despite the fact that these
imaging methods provide important information, we have to
take into account that the rate of false-positive as well as false-
negative results from these imaging methods is substantial and,
therefore, tissue confirmation by invasive staging methods are
mandatory for most situations, except if systemic disease is
already proven. Many studies have evaluated the value of CT and
PET for staging NSCLC over recent years. Since the N-stage is the
most discriminating descriptor for prognosis with the greatest
implication for decision making on treatment, the main focus in
staging NSCLC is on mediastinal lymph node staging.
In localized lung cancer confined to the lungs with or
without infiltration of the chest wall, accurate staging of the
mediastinal lymph node involvement is the most important
aspect for defining initial management. CT is very accurate
in detecting enlarged lymph nodes. Lymph node size itself,
however, is not very predictive in staging, since normal
size lymph nodes may contain metastases in up to 20% of
cases and enlarged lymph nodes of >1.0–1.5 cm may be
benign in up to 30%–40% [1]. For the clinical decision making
that is relevant to the patient this information is insufficient.
The use of PET with 2-[fluorine-18]fluoro-2-deoxy-
D-glucose (FDG) has proved to be clearly superior compared
with CT for mediastinal lymph node staging. Most reliable is
the fact that the negative predictive value of lymph nodes
assessed by PET is comparably high, as is that of
mediastinoscopy. Therefore, mediastinal lymph nodes which
are negative on a PET scan need no further assessment and
this information can be accepted for most patients with stage
I–II NSCLC. Exceptions are centrally located tumours or
tumours with a poor uptake of glucose on PET scan, such as
bronchial alveolar cell carcinomas.
Assessment of the lymph nodes by histology or cytology is
indicated for PET-positive lymph nodes in the mediastinum as
well as for enlarged lymph nodes of >1.5 cm on CT and the
above-mentioned situations in which PET has a high rate of
a false negativity. This recommendation is based on the fact
that the positive predictive value of the PET scan is only 79%
[2] and might be higher where inflammatory mediastinal
lymph node disease is endemic. Integrated PET–CT scans allow
a more precise anatomical correlation of the radionuclide
uptake and the anatomical structure within the mediastinum,
usually the lymph nodes, compared with a visual correlation of
the information by the reader. This improves the quality of
invasive staging.
invasive non-surgical staging
Invasive non-surgical techniques for biopsy of mediastinal
lymph nodes or pathologic tissue include transbronchial needle
aspiration (TBNA), either ‘blind’ or with the guidance of
endoscopic ultrasonography (EBUS–TBNA), and ultrasound-
guided fine-needle aspiration through the route of the
oesophagus, the so-called EUS–FNA. TBNA has been applied
for many years by a ‘blind’ technique, where the bronchoscopist
punctures lymph nodes adjacent to the tracheobronchial tree.
This might be successful when lymph nodes are enlarged and
located in areas that are clearly defined bronchoscopically by
landmarks from inside the tracheobronchial tree, such as the
subcarinal region (lymph node station 7) or at the
tracheobronchial angle (lymph node station 4). The sensitivity
is reported to be 76% and the false-negative rate is 29% in
clinical N2 disease (Table 1). The high false-negative rate for
a blind puncture is not surprising. Nevertheless, this technique
is valuable as a primary diagnostic test in the above-described
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circumstances or if EBUS-TBNA is not available. It can be
complemented by mediastinoscopy if the suspected proof of
cancer involvement of the lymph nodes fails.
EBUS–TBNA improves the accuracy compared with blind
TBNA and may allow successful puncture of lymph nodes that
are mildly enlarged and not completely adjacent to the
tracheobronchial tree. Histology can be provided for all lower
paratracheal and subcarinal lymph nodes, and even those in the
higher mediastinum. The limitations are lymph nodes in the
posterior and inferior part of the mediastinum. For these
situations EUS–FNA has to be used, which allows the puncture
of lymph nodes in the inferior mediastinum (lymph node
stations 8 and 9) as well as in the aorta–pulmonary window
(lymph node station 5) and in the posterior part of subcarinal
and paratracheal lymph nodes (lymph node stations 7 and 4).
A large meta-analysis reports a sensitivity of 88% with
a specificity of 91%, which results in a positive predictive value
of 98% and negative predictive value of 77% [2] (Table 1). The
combination of EBUS–FNA and EUS–FNA allows a near
complete minimal invasive mediastinal staging. Most of the
studies, however, have been performed in patients with a high
suspicion of lymph node involvement and lymph nodes are
enlarged and/or PET positive. Nevertheless, it is generally
accepted that these techniques are suitable to provide
histological confirmation of suspicious mediastinal lymph
nodes. It has to be recognized that due to their low negative
predictive value these techniques are insufficient to exclude
mediastinal lymph node disease and surgical staging is
indicated for those situations.
invasive surgical staging
Lymph nodes in the mediastinum can be surgically reached
either by cervical mediastinoscopy, video-assisted thoracoscopy
(VATS) or an open technique through a mini-thoracotomy.
Cervical mediastinoscopy is by far the most commonly used
technique and usually performed under general anaesthesia.
Through a small cervical incision above the sternum the
mediastinoscope is inserted and lymph node stations adjacent
to the trachea or the right and left main bronchus on both sides
can be assessed. This includes the highest mediastinal lymph
node station 1, the left and right superior paratracheal lymph
node station (2L and 2R), the left and right inferior
paratracheal station (4L and 4R), and the subcarinal lymph
node station (7). Lymph nodes can be biopsied or completely
resected. Some groups have further developed the technique
and perform a complete lymph node resection by video-assisted
mediastinoscopy (VAMLA). Even more extensive is the
technique of transcervical extended mediastinal lymph
adenectomy (TEMLA). These two techniques were developed
in order to completely remove all mediastinal lymph nodes in
order to minimize the false-negative results by finding even
micrometastases in lymph nodes. So far this technique is
applied by a few groups only and its clinical meaning has to be
assessed by further studies.
Mediastinoscopy is used by trained thoracic surgeons
routinely and morbidity of the procedure is very low in
experienced hands. The European Society of Thoracic Surgeons
(ESTS) created guidelines for preoperative as well as
intraoperative mediastinal staging. It is recommended that
the left and right superior as well as inferior paratracheal nodes
(2 and 4) and the subcarinal lymph nodes (7) are biopsied to
achieve a proper analysis of the extent of the disease in the
mediastinum. As in most invasive procedures, the quality of
mediastinoscopy depends on the experience of the surgeon and
varies substantially. The advantage of mediastinoscopy
compared with EUS–FNA is the more complete mediastinal
mapping. Not only lymph nodes which are indicated as
pathologic by imaging methods are assessed, but also lymph
nodes of normal size can be biopsied or even resected, as can
those on the contralateral side. The limitation of
mediastinoscopy is the fact that some stations are not
accessible for anatomic reasons, such as the station in the
aorta–pulmonary window (5) and the lower oesophageal lymph
nodes (8) or lymph nodes in the pulmonary ligament (9).
Additionally, lymph nodes in the upper posterior mediastinum
are not accessible. Nevertheless, mediastinoscopy remains the
gold standard for reliable mediastinal staging.
guidelines from the ESTS for baseline
mediastinal lymph node staging
The basic imaging modality in lung cancer is the CT scan of the
chest. If PET is not available, invasive staging is advised in every
patient since the accuracy of CT scan only is not sufficient for
mediastinal lymph node staging. An exception to this rule can
be made for patients with a peripheral stage-I NSCLC and
normal size lymph nodes. EBUS and EUS–TBNA are first
choice and sufficient when a metastasis can be proven. Negative
findings have to be confirmed by mediastinoscopy.
When PET is applied and mediastinal nodes are negative,
despite a tumour being PET-positive, no further tissue
confirmation is needed. The following subgroups are
exceptions to this rule: central tumours, low FDG uptake in the
primary tumour and enlarged lymph nodes >1.5 cm on CT. In
these situations invasive staging remains indicated. All
mediastinal lymph nodes that are positive on PET–CT scan
should be confirmed either cytologically or histologically. This
can be performed either by TBNA, EBUS–FNA or EUS–FNA.
Table 1. Value of techniques for staging metastatic mediastinal nodesa
Technique Sensitivity Specificity NPV PPV
% % % %
CT 57 82 83 56
PET 84 89 93 79
Blind TBNA 76 96 71 100
EUS–FNA 88 91 77 98
Mediastinoscopy 81 100 91 100
aProportion of patients with metastatic mediastinal nodes in the study
cohorts.
NPV, negative predictive value; PPV, positive predictive value; CT,
computed tomography; PET, positron emission tomography; TBNA,
transbronchial needle aspiration; EUS–FNA, endoscopic oesophageal
ultrasound-guided fine needle aspiration.
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As discussed above, the negative predictive value is low and
therefore a negative result must be confirmed by a cervical
mediastinoscopy.
The algorithm proposed by the ESTS (Figure 1) has to be
adopted in each institution according to the availability of the
various methods, especially PET–CT, skilled mediastinoscopists
or skilled invasive bronchoscopists with sufficient experience in
these techniques.
restaging after induction therapy
Patients which have been diagnosed initially as stage III disease
generally undergo induction chemo- or chemo/radiotherapy.
Restaging of the mediastinal lymph nodes prior to surgery is
necessary in order to avoid incomplete resection. It has been
shown that patients with complete resection after downstaging
would benefit from a surgical procedure. Imaging modalities
alone, such as CT scan, PET or PET–CT, are not accurate
enough for restaging, except for those with a complete
response after chemo- or chemo/radiotherapy. Tissue
information either by endoscopic techniques or by
mediastinoscopy or thoracoscopy is needed. Re-
mediastinoscopy is more difficult to perform due to extensive
scaring of the mediastinal structures and is associated with
a higher risk for morbidity. It is recommended that patients
who are foreseen as cases for induction therapy preferably
should be staged initially by an endoscopic technique (TBNA
or EBUS/EUS–TBNA) in order to reserve mediastinoscopy for
restaging. There are not yet sufficient data on endoscopic
techniques in restaging and, currently, each centre has to rely
on its available expertise.
disclosures
No significant relationships.
references
1. de Langen AJ, Raijmakers P, Riphagen I et al. The size of mediastinal lymph
nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardio
Thorac Surg 2006; 29: 26–29.
2. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung
cancer: a review of the current evidence. Chest 2003; 123: 137–146.
3. de Leyn P, Lardinois D, van Schil PE et al. ESTS guidelines for preoperative lymph
node staging for non-small cell lung cancer. Eur J Cardio Thorac Surg 2007; 32:
1–8.
Figure 1. Algorithm proposed by European Society of Thoracic Surgeons
for staging mediastinal lymph nodes (station 3).
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